Townsend, M <br/><br/>
Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.  [electronic resource] 

 -  Heart (British Cardiac Society)  Aug 2004 
 - e47 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1468-201X 
<br/><br/><label>Standard No.: </label>10.1136/hrt.2004.036236  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiparkinson Agents--adverse effects<br/>Cabergoline<br/>Ergolines--adverse effects<br/>Fibrosis--chemically induced<br/>Humans<br/>Male<br/>Middle Aged<br/>Parkinson Disease--drug therapy<br/>Pericarditis, Constrictive--chemically induced<br/>Pleura--pathology<br/>Pulmonary Fibrosis--chemically induced